Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)

von Moos Roger; Koeberle Dieter; Schacher Sabina; Hayoz Stefanie; Winterhalder Ralph C.; Roth Arnaud; Bodoky Gyorgy; Samaras Panagiotis; Berger Martin D.; Rauch Daniel; Saletti Piercarlo; Plasswilm Ludwig; Zwahlen Daniel; Meier Urs R.; Yan Pu; Izzo Paola; Klingbiel Dirk; Bartschi Daniela; Zaugg Kathrin

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)

【24h】

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)

机译：Neoadjuvant放射治疗与Capecitabine和Sorafenib在先进的KRAS突变直肠癌患者中：I / II期试验（SAKK 41/08）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: KRAS mutation occurs in w40% of locally advanced rectal cancers (LARCs). The multitarget tyrosine kinase inhibitor sorafenib has radiosensitising effects and might improve outcomes for standard preoperative chemoradiotherapy in patients with KRAS-mutated LARC.

机译：背景：KRAS突变发生在W40％的局部晚期直肠癌（LARC）中。 Multarget酪氨酸激酶抑制剂Sorafenib具有放射敏感效应，可以改善KRAS-突变LARC患者标准术前化学疗法的结果。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2018年第2018期|共8页
作者
von Moos Roger; Koeberle Dieter; Schacher Sabina; Hayoz Stefanie; Winterhalder Ralph C.; Roth Arnaud; Bodoky Gyorgy; Samaras Panagiotis; Berger Martin D.; Rauch Daniel; Saletti Piercarlo; Plasswilm Ludwig; Zwahlen Daniel; Meier Urs R.; Yan Pu; Izzo Paola; Klingbiel Dirk; Bartschi Daniela; Zaugg Kathrin;
展开▼
作者单位

Kantonsspital Graubunden Loestr 170 CH-7000 Chur Switzerland;

Kantonsspital St Gallen St Gallen Switzerland;

Kantonsspital Winterthur Winterthur Switzerland;

SAKK Coordinating Ctr Bern Switzerland;

Luzerner Kantonsspital Luzern Switzerland;

Univ Hosp Geneva Geneva Switzerland;

Szent Laszlo Teaching Hosp Budapest Hungary;

Univ Hosp Zurich Zurich Switzerland;

Inselspital Bern Bern Switzerland;

Regionalspital Thun Thun Switzerland;

IOSI Bellinzona Switzerland;

Kantonsspital St Gallen St Gallen Switzerland;

Kantonsspital Graubunden Loestr 170 CH-7000 Chur Switzerland;

Kantonsspital Winterthur Winterthur Switzerland;

Univ Hosp Zurich Zurich Switzerland;

Pathol CHUV Lausanne Switzerland;

SAKK Coordinating Ctr Bern Switzerland;

SAKK Coordinating Ctr Bern Switzerland;

Univ Hosp Zurich Zurich Switzerland;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Dose escalation; Chemoradiotherapy; Efficacy Tyrosine kinase inhibitor; Safety;

机译：剂量升级;化学疗法;疗效酪氨酸激酶抑制剂;安全;

相似文献

外文文献
中文文献
专利

1. Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08) [J] . von Moos Roger, Koeberle Dieter, Schacher Sabina, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2018,第期

机译：Neoadjuvant放射治疗与Capecitabine和Sorafenib在先进的KRAS突变直肠癌患者中：I / II期试验（SAKK 41/08）
2. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53 [J] . ChioreanE.G., SanghaniS., SchielM.A., Cancer chemotherapy and pharmacology. . 2012,第1期

机译：新辅助卡培他滨联合伊立替康联合基于卡培他滨的放化疗治疗局部晚期直肠癌的第二阶段和基因表达分析试验：Hoosier肿瘤学小组GI03-53
3. Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53 [J] . E. Gabriela Chiorean, Sonal Sanghani, Marissa A. Schiel, Cancer Chemotherapy and Pharmacology . 2012,第1期

机译：新辅助卡培他滨联合伊立替康联合基于卡培他滨的放化疗治疗局部晚期直肠癌的第二阶段和基因表达分析试验：Hoosier肿瘤学小组GI03-53
4. Neoadjuvant treatment in rectal cancer: do we always need radiotherapy-or can we risk assess locally advanced rectal cancer better? [C] . Rob Glynne-Jones St. Gallen EORTC Gastrointestinal Cancer Conference . 2012

机译：Neoadjuvant在直肠癌中治疗：我们总是需要放射治疗 - 或者我们是否可以更好地评估当地先进的直肠癌？
5. Intenzivnej?e neoadjuvantno zdravljenje lokalno napredovalnega raka danke =Intensified neoadjuvant treatment of locally advanced rectal cancer [D] . Golo, Danijela. 2018

机译：强烈的Neoadjuvant治疗局部晚期癌症射线=加强Neoadjuvant治疗局部晚期直肠癌
6. High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective randomised intergroup phase III trial SAKK 75/08 [O] . Martin Fehr, Hanne Hawle, Stefanie Hayoz, 2020

机译：新辅助治疗期间局部晚期食管癌患者的血栓栓塞事件发生率高。对前瞻性随机分组间III期临床试验SAKK 75/08的探索性分析
7. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07 [O] . Helbling, D., Bodoky, G., Gautschi, O., 2017

机译：野生型KRAS，局部晚期直肠癌（LARC）患者接受或不接受帕尼单抗的新辅助放化疗：一项随机，多中心，II期试验SAKK 41/07

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)

摘要

著录项

相似文献

相关主题

期刊订阅